Variability of HIV infections.

Genetic variation is the hallmark of infections with lentiviruses in general and the human immunodeficiency viruses (HIV-1, HIV-2) in particular. This article reviews both experimental evidence for the variability of the HIV genome during the course of an individual infection and mathematical models that outline the potential importance of antigenic variation as a major factor to drive disease progression. The essential idea is that the virus evades immune pressure by the continuous production of new mutants resistant to current immunological attack. This results in the accumulation of antigenic diversity during the asymptomatic period. The existence of an antigenic diversity threshold is derived from the asymmetric interaction between the virus quasispecies and the CD4 cell population: CD4 cells mount immune responses some of which are directed against specific HIV variants, but each virus strain can induce depletion of all CD4 cells and therefore impair immune responses regardless of their specificity. Therefore, increasing HIV diversity enables the virus population to escape from control by the immune system. In this context the observed genetic variability is responsible for the fact that the virus establishes a persistent infection without being cleared by the immune response and induces immunodeficiency disease after a long and variable incubation period. Mathematical biology has revealed a novel mechanism for viral pathogenesis.

[1]  M. Nowak HIV mutation rate , 1990, Nature.

[2]  A. Dalgleish,et al.  Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. , 1988, Virology.

[3]  M. Ascher,et al.  The initial immune response to HIV and immune system activation determine the outcome of HIV disease. , 1991, Journal of acquired immune deficiency syndromes.

[4]  A. Phillips,et al.  Prediction of progression to AIDS by analysis of CD4 lymphocyte counts in a haemophilic cohort. , 1989, AIDS.

[5]  P. Fultz,et al.  Identification and biologic characterization of an acutely lethal variant of simian immunodeficiency virus from sooty mangabeys (SIV/SMM). , 1989, AIDS research and human retroviruses.

[6]  J. Berzofsky,et al.  Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. , 1989, Journal of immunology.

[7]  T. H. Lee,et al.  Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120 , 1989, Journal of virology.

[8]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[9]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[10]  H. Vinters,et al.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. , 1987, Science.

[11]  J. Clements,et al.  Genomic changes associated with antigenic variation of visna virus durig persistent infection. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Whittle,et al.  Biological and molecular variability of human immunodeficiency virus type 2 isolates from The Gambia , 1990, Journal of virology.

[13]  J. Mullins,et al.  Sequence analysis and acute pathogenicity of molecularly cloned SIVSMM-PBj14 , 1990, Nature.

[14]  L. Pearl,et al.  Characterization of HIV‐1 neutralization escape mutants , 1989, AIDS.

[15]  M A Nowak,et al.  Models of interactions between HIV and other pathogens. , 1992, Journal of theoretical biology.

[16]  C. Cheng‐Mayer,et al.  Biologic features of HIV-1 that correlate with virulence in the host. , 1988, Science.

[17]  L. Loeb,et al.  Fidelity of HIV-1 reverse transcriptase. , 1988, Science.

[18]  L. Arthur,et al.  Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[20]  J. Berzofsky,et al.  A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160. , 1989, Science.

[21]  G. Shaw,et al.  Extensive variation of human immunodeficiency virus type-1 in vivo , 1988, Nature.

[22]  M A Nowak,et al.  Mathematical biology of HIV infections: antigenic variation and diversity threshold. , 1991, Mathematical biosciences.

[23]  V. Favier,et al.  Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Davide,et al.  Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. , 1990, Science.

[25]  P. Simmonds,et al.  Concurrent evolution of human immunodeficiency virus type 1 in patients infected from the same source , 2022 .

[26]  David Looney,et al.  Biologically diverse molecular variants within a single HIV-1 isolate , 1988, Nature.

[27]  Andreas Meyerhans,et al.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations , 1989, Cell.

[28]  T. Kirkwood,et al.  A model of human immunodeficiency virus infection in T helper cell clones. , 1990, Journal of theoretical biology.

[29]  R. Redfield,et al.  Type-restricted neutralization of molecular clones of human immunodeficiency virus. , 1988, Science.

[30]  J. Goudsmit Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts. , 1988, AIDS (London).

[31]  J. Berzofsky,et al.  Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. , 1991, Journal of immunology.

[32]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[33]  A. Profy,et al.  Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1 , 1990, Science.

[34]  C. Debouck,et al.  Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Ellis,et al.  Antigenic variation of caprine arthritis-encephalitis virus during persistent infection of goats. , 1987, The Journal of general virology.

[36]  R. Redfield,et al.  Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. , 1986, Science.

[37]  P Balfe,et al.  Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1 , 1990 .

[38]  S. Wain-Hobson HIV genome variability in vivo , 1989, AIDS.

[39]  M A Nowak,et al.  The evolutionary dynamics of HIV-1 quasispecies and the development of immunodeficiency disease. , 1990, AIDS.

[40]  C. Kuiken,et al.  HIV-1 V3 domain variation in brain and spleen of children with AIDS: tissue-specific evolution within host-determined quasispecies. , 1991, Virology.

[41]  M. Reitz,et al.  In vitro generation of an HTLV-III variant by neutralizing antibody. , 1986, Journal of immunology.

[42]  Robin A. Weiss,et al.  Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients , 1985, Nature.

[43]  C H Fox,et al.  The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. , 1989, Science.

[44]  M A Nowak,et al.  Antigenic diversity thresholds and the development of AIDS. , 1991, Science.

[45]  A. Collier,et al.  Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[46]  E. Werner,et al.  Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. , 1988, Immunology today.

[47]  M. Robert-Guroff,et al.  HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex , 1985, Nature.

[48]  D. Cooper,et al.  Primary HIV infection: host responses and intervention strategies. , 1991, AIDS.

[49]  C. Issel,et al.  Rapid emergence of novel antigenic and genetic variants of equine infectious anemia virus during persistent infection , 1986, Journal of virology.

[50]  J. Goedert,et al.  Natural history of human immunodeficiency virus infections in hemophiliacs: effects of T-cell subsets, platelet counts, and age. , 1987, Annals of internal medicine.

[51]  J. Goudsmit,et al.  Appearance of predictors of disease progression in relation to the development of AIDS , 1989, AIDS.